ELUT Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

3.10M

-43.31%

-0.120

-53.85%

3.35M

-44.44%

-0.120

-42.86%

3.60M

-42.52%

-0.120

-47.83%

Estimates Revision

The market is revising Downward the revenue expectations for Elutia Inc. (ELUT) for FY2025, with the revenue forecasts being adjusted by -23.2% over the past three months. During the same period, the stock price has changed by -45.08%.

Revenue Estimates for FY2025

Revise Downward

-23.2%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-28.8%

In Past 3 Month

Stock Price

Go Down

-45.08%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast ELUT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELUT is 3.50 USD with a low forecast of 2.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.670

Low

2.00

Averages

3.50

High

5.00

Current: 0.670

Low

2.00

Averages

3.50

High

5.00

Cantor Fitzgerald

Overweight -> Overweight

downgrade

$7 -> $5

2025-08-18

Reason

Cantor Fitzgerald

Price Target

$7 -> $5

2025-08-18

downgrade

Overweight -> Overweight

Reason

Cantor Fitzgerald lowered the firm's price target on Elutia to $5 from $7 and keeps an Overweight rating on the shares.

Lake Street

Buy

downgrade

$10 -> $8

2025-05-09

Reason

Lake Street

Price Target

$10 -> $8

2025-05-09

downgrade

Buy

Reason

Cantor Fitzgerald

Ross Osborn

Buy

Reiterates

2025-03-07

Reason

Cantor Fitzgerald

Ross Osborn

Price Target

2025-03-07

Reiterates

Buy

Reason

Valuation Metrics

The current forward P/E ratio for Elutia Inc (ELUT.O) is -1.44, compared to its 5-year average forward P/E of -2.85. For a more detailed relative valuation and DCF analysis to assess Elutia Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.85

Current PE

-1.44

Overvalued PE

-1.31

Undervalued PE

-4.39

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-5.92

Current EV/EBITDA

-5.07

Overvalued EV/EBITDA

-2.58

Undervalued EV/EBITDA

-9.27

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

2.29

Current PS

2.12

Overvalued PS

3.32

Undervalued PS

1.25

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ELUT News & Events

Events Timeline

No data

News

5.0

10-10Newsfilter

Elutia Welcomes Experienced MedTech Leader Guido J. Neels to Its Board of Directors

4.0

10-01TipRanks

Analysts' Picks: The 3 Most Trending Stocks as of October 1, 2025

8.5

09-17NASDAQ.COM

Biotech Stocks Surge After Hours Due to Trial Advancements, Funding Developments, and Anticipated Milestones

People Also Watch

Frequently Asked Questions

What is Elutia Inc (ELUT) stock price today?

The current price of ELUT is 0.67 USD — it has decreased -4.01 % in the last trading day.

What is Elutia Inc (ELUT)'s business?

Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Women’s Health and Cardiovascular markets. In Women’s Health, it offers SimpliDerm, a novel biological matrix that leverages the inherent science of natural healing processes. SimpliDerm's design uses human-based hydrated acellular dermal matrix (ADM), which mitigates inflammation and enhances tissue incorporation. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population. It is focused on advancing NXT-41x, a biomatrix that directly addresses the root causes of reconstruction infections following mastectomy. NXT-41x combines biologics and extended antibiotic release to provide protection while supporting tissue regeneration.

What is the price predicton of ELUT Stock?

What is Elutia Inc (ELUT)'s revenue for the last quarter?

Elutia Inc revenue for the last quarter amounts to 3.32M USD, decreased -9.26 % YoY.

What is Elutia Inc (ELUT)'s earnings per share (EPS) for the last quarter?

Elutia Inc. EPS for the last quarter amounts to -0.09 USD, decreased -400.00 % YoY.

What changes have occurred in the market's expectations for Elutia Inc (ELUT)'s fundamentals?

How many employees does Elutia Inc (ELUT). have?

Elutia Inc (ELUT) has 51 emplpoyees as of December 15 2025.

What is Elutia Inc (ELUT) market cap?

Today ELUT has the market capitalization of 29.80M USD.